These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 1418336)
21. Mechanism of teratogenic action of thalidomide. Vaisman B Teratology; 1996 May; 53(5):283-4. PubMed ID: 8879085 [No Abstract] [Full Text] [Related]
22. Methods of evaluating the alleged teratogenicity of environmental agents. Brent RL Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621 [No Abstract] [Full Text] [Related]
23. Fetal preventive medicine: teratogens and the unborn baby. Chernoff GF; Jones KL Pediatr Ann; 1981 Jun; 10(6):210-7. PubMed ID: 6265855 [No Abstract] [Full Text] [Related]
24. Fetal exposure to isotretinoin-an international problem. Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132 [TBL] [Abstract][Full Text] [Related]
25. Mechanism of known environmental teratogens: drugs and chemicals. Beckman DA; Brent RL Clin Perinatol; 1986 Sep; 13(3):649-87. PubMed ID: 3533369 [TBL] [Abstract][Full Text] [Related]
26. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Brent RL Pediatrics; 2004 Apr; 113(4 Suppl):957-68. PubMed ID: 15060188 [TBL] [Abstract][Full Text] [Related]
27. [Principles and concepts of teratogenesis. I. The teratogenic injury (author's transl)]. Rooze M Rev Med Brux; 1980 Oct; 1(8):523-33. PubMed ID: 6781025 [No Abstract] [Full Text] [Related]
28. Use of mammalian models in teratology. Palmer AK Prog Clin Biol Res; 1985; 163A():97-106. PubMed ID: 3969396 [No Abstract] [Full Text] [Related]
29. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Diav-Citrin O; Shechtman S; Gotteiner T; Arnon J; Ornoy A Teratology; 2001 May; 63(5):186-92. PubMed ID: 11320529 [TBL] [Abstract][Full Text] [Related]
30. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
32. Pregnant and panicked about pills? Call for advice. Shapiro JP US News World Rep; 2001 Mar; 130(9):61. PubMed ID: 11252442 [No Abstract] [Full Text] [Related]
33. Potential subversion of pregnancy prevention program in the managed care setting. Wilkin JK Arch Dermatol; 1997 Feb; 133(2):243-4. PubMed ID: 9041846 [No Abstract] [Full Text] [Related]
36. Prescription of teratogenic medications in United States ambulatory practices. Schwarz EB; Maselli J; Norton M; Gonzales R Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908 [TBL] [Abstract][Full Text] [Related]
37. [Estimation of the teratogenic risk associated with the taking of drugs at the beginning of pregnancy]. Goujard J Acquis Med Recent; 1981; 198():157-71. PubMed ID: 7315160 [No Abstract] [Full Text] [Related]
38. Human teratogens: delineating the phenotypic effects, the period of greatest sensitivity, the dose-response relationship and mechanisms of action. Holmes LB Prog Clin Biol Res; 1988; 281():177-91. PubMed ID: 3174711 [No Abstract] [Full Text] [Related]
39. Methods for predicting human birth defects. Clayson DB Prog Clin Biol Res; 1985; 163C():197-203. PubMed ID: 3991622 [No Abstract] [Full Text] [Related]
40. Thalidomide retrospective: what did we learn? Fraser FC Teratology; 1988 Sep; 38(3):201-2. PubMed ID: 3227489 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]